Highlights newsletter 2 SABCS 2012
This newsletter presents you the following presentations:
2. Eribulin mesylate is not superior to capecitabine in metastatic breast cancer
This newsletter presents you the following presentations:
2. Eribulin mesylate is not superior to capecitabine in metastatic breast cancer
Medical writer